Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 921 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis C Virus Clear all
Completed Phase 2 Interventional Results available

Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV

NCT01878799
View directory record Official record
Conditions
Hepatitis C, HIV
Interventions
GS-7977/GS- 5885 FDC
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Transplanting Hepatitis C Lungs Into Negative Lung Recipients

NCT03724149
View directory record Official record
Conditions
Lung Diseases
Interventions
Zepatier, Epclusa
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 67 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Sep 30, 2026, 8:03 AM EDT
Completed No phase listed Observational

Racial Difference in HCV/Host Interactions

NCT00071916
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
Little Rock, Arkansas • Memphis, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

NCT04042740
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Glecaprevir/Pibrentasvir (G/P)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Phase 2Phase 3 Interventional

Glecaprevir/Pibrentasvir for the Treatment of PTSD

NCT05446857
View directory record Official record
Conditions
PTSD
Interventions
Glecaprevir / Pibrentasvir Pill
Drug
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
19 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

NCT02825212
View directory record Official record
Conditions
Hepatitis C, Cryoglobulinemia
Interventions
Harvoni, Epclusa
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

NCT00703118
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Tibotec BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Sep 30, 2026, 8:03 AM EDT
Not listed No phase listed Observational

Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience

NCT02485262
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir and simeprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 30, 2026, 8:03 AM EDT
Completed No phase listed Observational

Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection

NCT01771653
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Not listed
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Sep 30, 2026, 8:03 AM EDT
Terminated Phase 2Phase 3 Interventional

A Health Intervention to Prevent Depression Hepatitis C Patients

NCT01890083
View directory record Official record
Conditions
Hepatitis C, Major Depressive Disorder
Interventions
Exercise, Health Education
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 30, 2026, 8:03 AM EDT
Not listed Phase 4 Interventional

Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics

NCT05895448
View directory record Official record
Conditions
Chronic Hepatitis C, People Who Inject Drugs
Interventions
velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .
Drug
Lead sponsor
Center For Hepatitis C, Atlanta, GA
Other
Eligibility
18 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Phase 3 Interventional

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

NCT00411385
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Sep 30, 2026, 8:03 AM EDT
Terminated No phase listed Observational

Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma

NCT00767936
View directory record Official record
Conditions
Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver, Hepatobiliary Cancers
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

NCT02249182
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years to 17 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

HCV Seek, Test and Rapid Treatment for Young PWID

NCT03627546
View directory record Official record
Conditions
Hepatitis C, Drug Use
Interventions
Rapid Treatment strategy, Usual Care (facilitated referral)
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 29 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes

NCT00722423
View directory record Official record
Conditions
Hepatitis C
Interventions
Integrated care model, Usual Care Model
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Palo Alto, California • San Diego, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

NCT00336479
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

NCT01458054
View directory record Official record
Conditions
Hepatitis C
Interventions
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Sep 30, 2026, 8:03 AM EDT
Completed No phase listed Observational

Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers

NCT00342641
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
815,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation

NCT01579162
View directory record Official record
Conditions
Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease
Interventions
Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Device
Lead sponsor
HepQuant, LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Phase 1Phase 2 Interventional

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

NCT04596475
View directory record Official record
Conditions
Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Interventions
glecaprevir/pibrentasvir (GLE/PIB)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

Sonoelastography: Ultrasound Method to Measure Liver Fibrosis

NCT01747772
View directory record Official record
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hepatitis C Virus (HCV) Coinfection, Hepatitis B Virus (HBV), Drug-Induced Liver Injury
Interventions
Shear Wave Sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 30, 2026, 8:03 AM EDT
Completed Not applicable Interventional

Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR

NCT02669966
View directory record Official record
Conditions
ESRD, Hepatitis C
Interventions
Kidney transplantation
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 30, 2026, 8:03 AM EDT
Withdrawn No phase listed Observational

Cell Bound Complement Activation Proteins as Markers of Liver Injury

NCT01025531
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 30, 2026, 8:03 AM EDT